Discontinued — last reported Q4 '17
PepsiCo Indefinite-Lived Research and Development Assets increased by 0.6% to $13.93B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.9%, from $14.21B to $13.93B. Over 5 years (FY 2020 to FY 2025), Indefinite-Lived Research and Development Assets shows a downward trend with a -4.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $17.74B | $17.29B | $17.13B | $16.60B | $15.74B | $15.84B | $14.31B | $14.27B | $14.33B | $14.29B | $13.73B | $13.68B | $13.68B | $13.73B | $13.70B | $14.21B | $14.21B | $13.61B | $13.85B | $13.93B |
| QoQ Change | — | -2.5% | -0.9% | -3.1% | -5.2% | +0.6% | -9.7% | -0.3% | +0.4% | -0.3% | -3.9% | -0.4% | -0.0% | +0.4% | -0.2% | +3.7% | +0.0% | -4.2% | +1.7% | +0.6% |
| YoY Change | — | — | — | — | -11.2% | -8.4% | -16.5% | -14.0% | -9.0% | -9.8% | -4.0% | -4.2% | -4.6% | -4.0% | -0.2% | +3.8% | +3.9% | -0.8% | +1.1% | -1.9% |